Arthritis Research
Arthritis is an inflammatory disease of the joints, including the synovium, cartilage, bone, and supporting tissues. It is the leading cause of disability in the US and there are over 100 different types of the disease. The most common types of arthritis are osteoarthritis, rheumatoid arthritis and gout.
Arthritis Research Products Targets
- Matrix Metalloprotease (16)
- Cell Adhesion Molecule (21)
- Leukotriene and Related Receptor (13)
- Others (7)
- Glucocorticoid Receptor (9)
- Cyclooxygenase (24)
- Complement (2)
- Focal Adhesion Kinase (4)
- Chemokine CXC Receptor (9)
- Chemokine CC Receptor (13)
- p38 MAPK (16)
- Janus N-terminal Kinase (12)
- Calcium-Sensitive Protease Modulator (12)
- Rho-Kinases (9)
- NO donors and precursors (9)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- Cytokine (15)
Products for Arthritis Research - Page 16
- Cat.No. Product Name Information/Activity
-
BCC6229
LDV FITC
1207610-07-8
-
BCC6332
Leukadherin 1
Leukadherin-1 is a specific agonist of complement receptor 3 (CR3) and the leukocyte surface αMβ2 integrin CD11b/CD18.
-
BCC3943
MNS
MNS is a potent and selective inhibitor of Src and Syk tyrosine kinases.
-
BCC7458
OGT 2115
OGT 2115 is a potent, cell-permeable and orally active heparanase inhibitor with an IC50 of 0.4 μM. OGT 2115 has anti-angiogenic properties (IC50 of 1 μM). OGT 2115 also inhibits heparan sulfate degradation activity.
-
BCC6275
P11
848644-86-0
-
BCC6105
PM 102
1234564-95-4
-
BCC7694
RGDS peptide
Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function, decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS and MMP-9.
-
BCC7894
RWJ 50271
RWJ 50271 is an selective inhibitor of lymphocyte function-associated antigen-1/intercellular adhesion molecule-1(LFA-1/ICAM-1) interaction with an IC50 of 5.0 μM (HL60 cells).
-
BCC6216
TC-I 15
916734-43-5
-
BCC6080
TCS 2314
TCS 2314 (compound 3) is orally active and selective very late antigen-4 (VLA-4, α4β1, CD49d/CD29) antagonist with an IC50 of 4.4 nM.


